BR112022019338A2 - Tratamento preventivo de enxaqueca - Google Patents
Tratamento preventivo de enxaquecaInfo
- Publication number
- BR112022019338A2 BR112022019338A2 BR112022019338A BR112022019338A BR112022019338A2 BR 112022019338 A2 BR112022019338 A2 BR 112022019338A2 BR 112022019338 A BR112022019338 A BR 112022019338A BR 112022019338 A BR112022019338 A BR 112022019338A BR 112022019338 A2 BR112022019338 A2 BR 112022019338A2
- Authority
- BR
- Brazil
- Prior art keywords
- preventive treatment
- migraine
- migraine preventive
- rimegepant
- pharmaceutical compositions
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title abstract 3
- 206010027599 migraine Diseases 0.000 title abstract 3
- 230000003449 preventive effect Effects 0.000 title abstract 3
- KRNAOFGYEFKHPB-ANJVHQHFSA-N [(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound C1([C@H]2[C@@H](C3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)N)=CC=CC(F)=C1F KRNAOFGYEFKHPB-ANJVHQHFSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229950004372 rimegepant Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
TRATAMENTO PREVENTIVO DE ENXAQUECA. A presente invenção refere-se a métodos para o tratamento preventivo de enxaqueca, administrando a um paciente em necessidade do mesmo rimegepant ou um sal farmaceuticamente aceitável do mesmo. Composições farmacêuticas compreendendo rimegepant e kits que incluem as composições farmacêuticas e instruções também são divulgadas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001341P | 2020-03-29 | 2020-03-29 | |
| US202063111138P | 2020-11-09 | 2020-11-09 | |
| US202063125247P | 2020-12-14 | 2020-12-14 | |
| PCT/US2021/024551 WO2021202321A1 (en) | 2020-03-29 | 2021-03-29 | Preventative treatment of migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019338A2 true BR112022019338A2 (pt) | 2022-12-06 |
Family
ID=77929752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019338A BR112022019338A2 (pt) | 2020-03-29 | 2021-03-29 | Tratamento preventivo de enxaqueca |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230321066A1 (pt) |
| EP (1) | EP4125899A4 (pt) |
| JP (1) | JP2023533634A (pt) |
| KR (1) | KR20230015324A (pt) |
| CN (1) | CN115697335A (pt) |
| AU (1) | AU2021247101A1 (pt) |
| BR (1) | BR112022019338A2 (pt) |
| CA (1) | CA3176432A1 (pt) |
| IL (1) | IL296872A (pt) |
| MX (1) | MX2022012001A (pt) |
| WO (1) | WO2021202321A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117425728A (zh) * | 2022-03-10 | 2024-01-19 | 宁波酶赛生物工程有限公司 | 用于合成乌布吉泮中间体的生物催化剂和方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020509081A (ja) * | 2017-02-15 | 2020-03-26 | モレキュラー インフュージョンズ、エルエルシー | 製剤 |
| WO2018236873A1 (en) * | 2017-06-19 | 2018-12-27 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION |
| MX2020009856A (es) * | 2018-03-25 | 2020-10-08 | Biohaven Pharm Holding Co Ltd | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). |
| WO2020008402A2 (en) * | 2018-07-05 | 2020-01-09 | Allergan Pharmaceuticals International Limited | Combination therapy with cgrp antagonists and clostridial derivatives |
| BR112022016790A2 (pt) * | 2020-02-27 | 2022-11-08 | Biohaven Pharm Holding Co Ltd | Forma de dosagem oral de dispersão rápida de rimegepant |
-
2021
- 2021-03-29 BR BR112022019338A patent/BR112022019338A2/pt not_active Application Discontinuation
- 2021-03-29 EP EP21780045.7A patent/EP4125899A4/en active Pending
- 2021-03-29 CN CN202180024742.6A patent/CN115697335A/zh active Pending
- 2021-03-29 IL IL296872A patent/IL296872A/en unknown
- 2021-03-29 MX MX2022012001A patent/MX2022012001A/es unknown
- 2021-03-29 KR KR1020227037259A patent/KR20230015324A/ko unknown
- 2021-03-29 WO PCT/US2021/024551 patent/WO2021202321A1/en unknown
- 2021-03-29 US US17/912,545 patent/US20230321066A1/en not_active Abandoned
- 2021-03-29 JP JP2022558094A patent/JP2023533634A/ja active Pending
- 2021-03-29 AU AU2021247101A patent/AU2021247101A1/en active Pending
- 2021-03-29 CA CA3176432A patent/CA3176432A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL296872A (en) | 2022-11-01 |
| US20230321066A1 (en) | 2023-10-12 |
| JP2023533634A (ja) | 2023-08-04 |
| KR20230015324A (ko) | 2023-01-31 |
| EP4125899A1 (en) | 2023-02-08 |
| EP4125899A4 (en) | 2024-06-12 |
| MX2022012001A (es) | 2022-10-21 |
| CA3176432A1 (en) | 2021-10-07 |
| WO2021202321A1 (en) | 2021-10-07 |
| AU2021247101A1 (en) | 2022-11-17 |
| CN115697335A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021009595A2 (pt) | Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres | |
| PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
| BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015011497A2 (pt) | composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112014000240A2 (pt) | derivados de benzilamina como inibidores de calicreína plasmática | |
| BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
| MY195194A (en) | Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors | |
| BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
| BRPI0607536A2 (pt) | tratamento de dor | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| BR112014023423A2 (pt) | terapia de combinação | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: PFIZER IRELAND PHARMACEUTICALS (IE) |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |